{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:33:25Z","timestamp":1792100005321,"version":"4.4.0"},"reference-count":272,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"publisher","award":["13-2025-0016"],"award-info":[{"award-number":["13-2025-0016"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-KH136120"],"award-info":[{"award-number":["RS-2023-KH136120"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-00519649"],"award-info":[{"award-number":["RS-2025-00519649"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drup.2026.101412","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:09:56Z","timestamp":1778108996000},"page":"101412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Breaking immune isolation in glioblastoma"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8397-1691","authenticated-orcid":false,"given":"Ji-Yong","family":"Sung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7211-729X","authenticated-orcid":false,"given":"Kihwan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28372-y","article-title":"Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target","volume":"13","author":"Abdelfattah","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102066","article-title":"Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy","volume":"8","author":"Abed","year":"2023","journal-title":"ESMO Open"},{"issue":"20","key":"10.1016\/j.drup.2026.101412_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015037","article-title":"Glioblastoma Immunotherapy: a systematic review of the present strategies and prospects for advancements","volume":"24","author":"Agosti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.drup.2026.101412_bib4","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/1878-0261.13598","article-title":"IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review","volume":"18","author":"Ahmad","year":"2024","journal-title":"Mol. Oncol."},{"issue":"S2","key":"10.1016\/j.drup.2026.101412_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/2051-1426-3-S2-O11","article-title":"Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial","volume":"3","author":"Ahmed","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","article-title":"Role of T cells in cancer immunotherapy: Opportunities and challenges","volume":"1","author":"Ahmed","year":"2023","journal-title":"Cancer Pathog. Ther."},{"issue":"3","key":"10.1016\/j.drup.2026.101412_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ph18030376","article-title":"A 5-Year Update on the Clinical Development of Cancer Cell-Based Vaccines for Glioblastoma Multiforme","volume":"18","author":"Alkayyal","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/icb.2017.8","article-title":"Targeting A2 adenosine receptors in cancer","volume":"95","author":"Allard","year":"2017","journal-title":"Immunol. & Cell Biol."},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14712598.2024.2357714","article-title":"Next-generation CD40 agonists for cancer immunotherapy","volume":"24","author":"Andersson","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.drup.2026.101412_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/neuonc\/noac239","article-title":"Exploiting radiation immunostimulatory effects to improve glioblastoma outcome","volume":"25","author":"Awada","year":"2023","journal-title":"Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1042\/BST20210961","article-title":"Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance","volume":"50","author":"Balasubramanian","year":"2022","journal-title":"Biochem. Soc. Trans."},{"issue":"8","key":"10.1016\/j.drup.2026.101412_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26083503","article-title":"Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases","volume":"26","author":"Barcan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48116-2","article-title":"Single-cell analysis reveals diversity of tumor-associated macrophages and their interactions with T lymphocytes in glioblastoma","volume":"13","author":"Batchu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101412_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02251-2","article-title":"Immunotherapy for glioblastoma: the promise of combination strategies","volume":"41","author":"Bausart","year":"2022","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"6024","key":"10.1016\/j.drup.2026.101412_bib16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib17","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ymthe.2025.03.004","article-title":"CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials","volume":"33","author":"Begley","year":"2025","journal-title":"Mol. Ther."},{"issue":"28","key":"10.1016\/j.drup.2026.101412_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111003119","article-title":"STING activation promotes robust immune response and NK cell\u2013mediated tumor regression in glioblastoma models","volume":"119","author":"Berger","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"45","key":"10.1016\/j.drup.2026.101412_bib19","doi-asserted-by":"crossref","first-page":"31411","DOI":"10.1039\/D3RA01153D","article-title":"Engineering the glioblastoma microenvironment with bioactive nanoparticles for effective immunotherapy","volume":"13","author":"Blanchard","year":"2023","journal-title":"RSC Adv."},{"issue":"20","key":"10.1016\/j.drup.2026.101412_bib20","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1158\/1078-0432.CCR-21-1914","article-title":"Intratumoral delivery of STING agonist results in clinical responses in canine glioblastoma","volume":"27","author":"Boudreau","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.drup.2026.101412_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14164032","article-title":"Adenosine targeting as a new strategy to decrease glioblastoma aggressiveness","volume":"14","author":"Bova","year":"2022","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.drup.2026.101412_bib22","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.drup.2026.101412_bib23","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.drup.2026.101412_bib24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro-Oncol."},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101412_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coviro.2015.05.007","article-title":"Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus","volume":"13","author":"Brown","year":"2015","journal-title":"Curr. Opin. Virol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","article-title":"Mitochondrial dynamics controls T cell fate through metabolic programming","volume":"166","author":"Buck","year":"2016","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.drup.2026.101412_bib28","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.trecan.2020.05.011","article-title":"DNA Damage Repair Deficiency in Prostate Cancer","volume":"6","author":"Burdak-Rothkamm","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101412_bib29","first-page":"10","article-title":"Machine learning\u2013based new classification for immune infiltration of gliomas","volume":"19","author":"Burger","year":"2024","journal-title":"Plos One"},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/nov245","article-title":"Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study","volume":"18","author":"Butowski","year":"2016","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.drup.2026.101412_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00641","article-title":"The Role of Fatty Acid Oxidation in the Metabolic Reprograming of Activated\u00e2\u20ac\u2030T-Cells","volume":"5","author":"Byersdorfer","year":"2014","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.drup.2026.101412_bib32","doi-asserted-by":"crossref","first-page":"23746","DOI":"10.1021\/acsnano.3c07555","article-title":"Biomimetic Macrophage Membrane-Camouflaged Nanoparticles Induce Ferroptosis by Promoting Mitochondrial Damage in Glioblastoma","volume":"17","author":"Cao","year":"2023","journal-title":"ACS Nano"},{"issue":"14","key":"10.1016\/j.drup.2026.101412_bib33","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-09-3073","article-title":"Angiopoietin-2 Interferes with Anti-VEGFR2\u2013Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas","volume":"16","author":"Chae","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101412_bib34","article-title":"situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response","volume":"26","author":"Chellen","year":"2024","journal-title":"Mater. Today Bio"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-024-05497-5","article-title":"Activated kynurenine pathway metabolism by YKL-40 establishes an inhibitory immune microenvironment and drives glioblastoma development","volume":"82","author":"Chen","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-023-00551-z","article-title":"Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy","volume":"12","author":"Chen","year":"2024","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib37","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00560-6","article-title":"MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma","volume":"12","author":"Chen","year":"2024","journal-title":"Biomark. Res."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/neuonc\/noad211","article-title":"Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?","volume":"26","author":"Chen","year":"2024","journal-title":"Neuro-Oncol."},{"issue":"18","key":"10.1016\/j.drup.2026.101412_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cells14181458","article-title":"Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib40","article-title":"Modulating tumor-associated macrophages through CSF1R inhibition: a potential therapeutic strategy for HNSCC","volume":"23","author":"Chen","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib41","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101412_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103865","article-title":"Carbon ion combined photon radiotherapy induces ferroptosis via NCOA4-mediated ferritinophagy in glioblastoma","volume":"86","author":"Chen","year":"2025","journal-title":"Redox Biol."},{"issue":"9-10","key":"10.1016\/j.drup.2026.101412_bib43","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.ccr.2012.10.021","article-title":"Mixed valency and metal\u2013metal quadruple bonds","volume":"257","author":"Chisholm","year":"2013","journal-title":"Coord. Chem. Rev."},{"issue":"591","key":"10.1016\/j.drup.2026.101412_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.drup.2026.101412_bib45","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp. & Mol. Med."},{"issue":"9","key":"10.1016\/j.drup.2026.101412_bib46","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051519","article-title":"Metabolic Barriers to Glioblastoma Immunotherapy","volume":"15","author":"Choudhary","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-06909-7","article-title":"Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma","volume":"15","author":"Cocito","year":"2025","journal-title":"Sci. Rep."},{"issue":"64","key":"10.1016\/j.drup.2026.101412_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8 + T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci. Immunol."},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib50","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"issue":"18","key":"10.1016\/j.drup.2026.101412_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cells13181574","article-title":"Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets","volume":"13","author":"Cortes Ballen","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib52","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-025-03497-2","article-title":"Glioblastoma metabolomics: uncovering biomarkers for diagnosis, prognosis and targeted therapy","volume":"44","author":"Costantini","year":"2025","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.drup.2026.101412_bib53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-020-03408-9","article-title":"Convection-enhanced drug delivery for glioblastoma: a review","volume":"151","author":"D\u2019Amico","year":"2021","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.drup.2026.101412_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.770390","article-title":"Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End","volume":"12","author":"Datsi","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib55","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","article-title":"Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma","volume":"57","author":"De Leo","year":"2024","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.drup.2026.101412_bib56","doi-asserted-by":"crossref","first-page":"iii43","DOI":"10.1093\/neuonc\/nou209.5","article-title":"Oncolytic Polio\/Rhinovirus Recombinant (Pvsripo) in Recurrent Glioblastoma (Gbm): First Phase I Clinical Trial Evaluating the Intratumoral Administration","volume":"16","author":"Desjardins","year":"2014","journal-title":"Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent Glioblastoma Treated with Recombinant Poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-biodatasci-102523-103640","article-title":"Spatially Resolved Single-Cell Omics: Methods, Challenges, and Future Perspectives","volume":"7","author":"Dezem","year":"2024","journal-title":"Annu. Rev. Biomed. Data Sci."},{"key":"10.1016\/j.drup.2026.101412_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1039\/D4PM00263F","article-title":"Comprehensive review on glioblastoma: nanotechnology, immunotherapy and combined therapeutic approaches","volume":"2","author":"Dhiman","year":"2025","journal-title":"RSC Pharm."},{"issue":"9","key":"10.1016\/j.drup.2026.101412_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094460","article-title":"Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction","volume":"22","author":"Di Ianni","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib62","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-07272-x","article-title":"Lactate at the crossroads of tumor metabolism and immune escape: a new frontier in cancer therapy","volume":"23","author":"Dong","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib63","article-title":"Mitochondrial metabolism and cancer therapeutic innovation","volume":"10","author":"Du","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.drup.2026.101412_bib64","article-title":"The spatial multi-omics revolution in cancer therapy: Precision redefined","volume":"5","author":"Du","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"19","key":"10.1016\/j.drup.2026.101412_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16193300","article-title":"Blood\u2013Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges","volume":"16","author":"Duan","year":"2024","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib66","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/s41423-020-0365-3","article-title":"Enforced PGC-1\u03b1 expression promotes CD8 T cell fitness, memory formation and antitumor immunity","volume":"18","author":"Dumauthioz","year":"2020","journal-title":"Cell. & Mol. Immunol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib67","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-025-02880-9","article-title":"Liquid biopsies for the monitoring of gliomas and brain metastases in adults","volume":"149","author":"Dwarshuis","year":"2025","journal-title":"Acta Neuropathol."},{"issue":"12","key":"10.1016\/j.drup.2026.101412_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009175","article-title":"Co-evolution of glioma and immune microenvironment","volume":"12","author":"Elguindy","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101412_bib69","first-page":"1","article-title":"Hypoxia Potentiates Glioma-Mediated Immunosuppression","volume":"6","author":"Eltzschig","year":"2011","journal-title":"PLoS ONE"},{"issue":"15","key":"10.1016\/j.drup.2026.101412_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153698","article-title":"Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy","volume":"14","author":"Fekrirad","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101412_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384249","article-title":"Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments","volume":"15","author":"Feldman","year":"2024","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.drup.2026.101412_bib72","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101412_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1688995","article-title":"Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy","volume":"16","author":"Frlic","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101412_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1098482","article-title":"Roles of STAT3 in the pathogenesis and treatment of glioblastoma","volume":"11","author":"Fu","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.drup.2026.101412_bib75","article-title":"Single-cell and spatial transcriptomic insights into glioma cellular heterogeneity and metabolic adaptations","volume":"16","author":"Fu","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.drup.2026.101412_bib76","doi-asserted-by":"crossref","DOI":"10.4110\/in.2021.21.e21","article-title":"Mechanisms Underlying the Role of Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad","volume":"21","author":"Ge","year":"2021","journal-title":"Immune Netw."},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib77","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3174\/ajnr.A7488","article-title":"Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma","volume":"43","author":"George","year":"2022","journal-title":"Am. J. Neuroradiol."},{"issue":"9","key":"10.1016\/j.drup.2026.101412_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092292","article-title":"The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma","volume":"10","author":"Ghosh","year":"2022","journal-title":"Biomedicines"},{"issue":"771","key":"10.1016\/j.drup.2026.101412_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1168","article-title":"Protumoral lipid droplet\u2013loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted","volume":"16","author":"Governa","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.drup.2026.101412_bib80","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","article-title":"Integrative spatial analysis reveals a multi-layered organization of glioblastoma","volume":"187","author":"Greenwald","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20469-6","article-title":"Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy","volume":"12","author":"Gromeier","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101412_bib82","article-title":"Enhancing T cell infiltration in glioblastoma: a review article on challenges and therapeutic strategies","volume":"45","author":"Habibi","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"issue":"20","key":"10.1016\/j.drup.2026.101412_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj3301","article-title":"Hypoxia coordinates the spatial landscape of myeloid cells within glioblastoma to affect survival","volume":"10","author":"Haley","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101412_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101435","article-title":"Memory CD8+ T cell responses to cancer","volume":"49","author":"Han","year":"2020","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24347-7","article-title":"Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma","volume":"12","author":"van Hooren","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.drup.2026.101412_bib86","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-022-01724-w","article-title":"The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies","volume":"39","author":"Hosseinalizadeh","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.drup.2026.101412_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295218","article-title":"Antigen-presenting B cells promote TCF-1+ PD1- stem-like CD8+ T-cell proliferation in glioblastoma","volume":"14","author":"Hou","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib88","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01775-1","article-title":"CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks","volume":"22","author":"Hovhannisyan","year":"2023","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/mef2.61","article-title":"Oncolytic viral therapy as promising immunotherapy against glioma","volume":"2","author":"Hu","year":"2023","journal-title":"MedComm Future Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib90","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib91","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01255-x","article-title":"Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. & Oncol."},{"issue":"9","key":"10.1016\/j.drup.2026.101412_bib92","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1093\/neuonc\/noaf099","article-title":"Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade","volume":"27","author":"Hung","year":"2025","journal-title":"Neuro-Oncol."},{"issue":"14","key":"10.1016\/j.drup.2026.101412_bib93","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.7150\/thno.114257","article-title":"Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy","volume":"15","author":"Ijaz","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib94","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.drup.2026.101412_bib95","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1021\/acs.chemrev.5b00109","article-title":"Synthetic Nanoparticles for Vaccines and Immunotherapy","volume":"115","author":"Irvine","year":"2015","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65907-3","article-title":"Prognostic relevance of high expression of kynurenine pathway markers in glioblastoma","volume":"14","author":"Jacquerie","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib97","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3171\/2016.1.JNS151591","article-title":"Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies","volume":"126","author":"Jahangiri","year":"2017","journal-title":"J. Neurosurg."},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib98","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/WCO.0000000000000988","article-title":"T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies","volume":"34","author":"Jansen","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib99","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae503","article-title":"Long-range alternative splicing contributes to neoantigen specificity in glioblastoma","volume":"25","author":"Ji","year":"2024","journal-title":"Brief. Bioinforma."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib100","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01405-9","article-title":"Exploiting RIG-I-like receptor pathway for cancer immunotherapy","volume":"16","author":"Jiang","year":"2023","journal-title":"J. Hematol. & Oncol."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020229","article-title":"Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib102","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.drup.2026.101412_bib103","first-page":"7","article-title":"Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response","volume":"23","author":"Kang","year":"2025","journal-title":"PLOS Biol."},{"issue":"7948","key":"10.1016\/j.drup.2026.101412_bib104","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","article-title":"Single-cell spatial immune landscapes of primary and metastatic brain tumours","volume":"614","author":"Karimi","year":"2023","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.drup.2026.101412_bib105","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/neuonc\/nox079","article-title":"The interplay between metabolic remodeling and immune regulation in glioblastoma","volume":"19","author":"Kesarwani","year":"2017","journal-title":"Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib106","article-title":"Radiomics for characterization of the glioma immune microenvironment","volume":"7","author":"Khalili","year":"2023","journal-title":"npj Precis. Oncol."},{"issue":"20","key":"10.1016\/j.drup.2026.101412_bib107","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1158\/1078-0432.CCR-20-1135","article-title":"PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?","volume":"26","author":"Khasraw","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib108","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"issue":"19","key":"10.1016\/j.drup.2026.101412_bib109","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1016\/j.cell.2024.07.030","article-title":"Macrophage-mediated myelin recycling fuels brain cancer malignancy","volume":"187","author":"Kloosterman","year":"2024","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.drup.2026.101412_bib110","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00262-014-1561-8","article-title":"Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells","volume":"63","author":"Kosaka","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib111","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11060-023-04552-8","article-title":"Adjuvant convection-enhanced delivery for the treatment of brain tumors","volume":"166","author":"Kreatsoulas","year":"2024","journal-title":"J. Neuro-Oncol."},{"issue":"10","key":"10.1016\/j.drup.2026.101412_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009449","article-title":"Inhibitory Fc\u03b3 receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma","volume":"12","author":"Ku","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.drup.2026.101412_bib113","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2306973121","article-title":"Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy","volume":"121","author":"Kudruk","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/intimm\/dxaa046","article-title":"Immune metabolism in PD-1 blockade-based cancer immunotherapy","volume":"33","author":"Kumar","year":"2021","journal-title":"Int. Immunol."},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib115","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","article-title":"Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan\u2013Kynurenine\u2013Aryl Hydrocarbon Axis","volume":"25","author":"Labadie","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.drup.2026.101412_bib116","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1158\/1078-0432.CCR-17-3573","article-title":"IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma","volume":"24","author":"Ladomersky","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.drup.2026.101412_bib117","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: First Approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.drup.2026.101412_bib118","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101412_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1661327","article-title":"Targeting the neuroimmune axis in glioblastoma: emerging strategies for precision immunotherapy","volume":"16","author":"Lang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101412_bib120","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the Immune System: The Dynamic Duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib121","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med."},{"issue":"3","key":"10.1016\/j.drup.2026.101412_bib122","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.tem.2020.12.005","article-title":"Roles of TGF-\u03b2 Superfamily Proteins in Extravillous Trophoblast Invasion","volume":"32","author":"Li","year":"2021","journal-title":"Trends Endocrinol. & Metab."},{"key":"10.1016\/j.drup.2026.101412_bib123","article-title":"Immune landscape-based machine-learning\u2013assisted subclassification, prognosis, and immunotherapy prediction for glioblastoma","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2023.11.012","article-title":"Targeting the chromatin structural changes of antitumor immunity","volume":"14","author":"Li","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.drup.2026.101412_bib125","article-title":"Interactions between glioblastoma and myeloid cells","volume":"13","author":"Li","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.drup.2026.101412_bib126","article-title":"New Insights into Monocyte-Derived Macrophages in Glioblastoma","volume":"8","author":"Li","year":"2025","journal-title":"Research"},{"issue":"11","key":"10.1016\/j.drup.2026.101412_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116463","article-title":"Metabolic regulation of immunity in the tumor microenvironment","volume":"44","author":"Li","year":"2025","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.drup.2026.101412_bib128","doi-asserted-by":"crossref","first-page":"388","DOI":"10.5483\/BMBRep.2024-0031","article-title":"Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy","volume":"57","author":"Lim","year":"2024","journal-title":"BMB Rep."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib129","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib130","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.drup.2026.101412_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib132","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.drup.2026.101412_bib133","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. & Mol. Immunol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib134","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning cold tumors into hot tumors to ignite immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101412_bib135","doi-asserted-by":"crossref","DOI":"10.34133\/bmr.0133","article-title":"Combined Strategies for Nanodrugs Noninvasively Overcoming the Blood\u2013Brain Barrier and Actively Targeting Glioma Lesions","volume":"29","author":"Liu","year":"2025","journal-title":"Biomater. Res."},{"issue":"3","key":"10.1016\/j.drup.2026.101412_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006522","article-title":"Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors","volume":"11","author":"Lontos","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib137","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163452","article-title":"Understanding and therapeutically exploiting cGAS\/STING signaling in glioblastoma","volume":"134","author":"Low","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib138","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib139","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trecan.2024.11.011","article-title":"Turning cold into hot: emerging strategies to fire up the tumor microenvironment","volume":"11","author":"Ma","year":"2025","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib140","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","article-title":"Macrophage diversity in cancer revisited in the era of single-cell omics","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol."},{"issue":"19","key":"10.1016\/j.drup.2026.101412_bib141","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26199554","article-title":"Overcoming Immune Therapy Resistance in Cancer Through Innate Immune Reprogramming","volume":"26","author":"Mandracci","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101412_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01848","article-title":"Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study","volume":"10","author":"Marchini","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib143","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib144","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020186","article-title":"Virus-Based Immunotherapy of Glioblastoma","volume":"11","author":"Martikainen","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib145","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54129-w","article-title":"Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker","volume":"15","author":"Martins","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.drup.2026.101412_bib146","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17111881","article-title":"The Metabolic Orchestration of Immune Evasion in Glioblastoma: From Molecular Perspectives to Therapeutic Vulnerabilities","volume":"17","author":"Medikonda","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib147","article-title":"Phase 1b\/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma","volume":"6","author":"Mendez","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"issue":"314","key":"10.1016\/j.drup.2026.101412_bib148","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac6522","article-title":"Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle","volume":"7","author":"Miller","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib149","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.celrep.2019.03.029","article-title":"HIF-1\u03b1 Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma","volume":"27","author":"Miska","year":"2019","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib150","article-title":"Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains","volume":"5","author":"Moffet","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.drup.2026.101412_bib151","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.696402","article-title":"Targeting Immunometabolism in Glioblastoma","volume":"11","author":"Mohan","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib152","doi-asserted-by":"crossref","DOI":"10.1038\/s43246-024-00721-y","article-title":"Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma","volume":"6","author":"Mokarram","year":"2025","journal-title":"Commun. Mater."},{"key":"10.1016\/j.drup.2026.101412_bib153","article-title":"Integration of omics data in the diagnosis and therapy of glioblastoma","author":"M\u00f6ller","year":"2025","journal-title":"Brain Pathol."},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib154","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101412_bib155","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.omto.2022.02.012","article-title":"A novel TanCAR targeting IL13R\u03b12 and EphA2 for enhanced glioblastoma therapy","volume":"24","author":"Muhammad","year":"2022","journal-title":"Mol. Ther. - Oncolytics"},{"key":"10.1016\/j.drup.2026.101412_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107039","article-title":"A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment","volume":"207","author":"Murugesan","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib157","article-title":"State of the neoadjuvant therapy for glioblastoma multiforme\u2014Where do we stand?","volume":"6","author":"Nabian","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"issue":"10","key":"10.1016\/j.drup.2026.101412_bib158","first-page":"3391","article-title":"R.R., et al., Role of Colony Stimulating Factor 1 (CSF-1) and Its Receptor CSF1R: Macrophage Repolarization for Glioblastoma Treatment. ACS Pharmacology & Translational","volume":"8","author":"Naik","year":"2025","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib159","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib160","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib161","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.adro.2018.11.005","article-title":"Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas","volume":"4","author":"Nesseler","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib162","article-title":"Current strategies and novel immunotherapeutic approaches for overcoming immune resistance in glioblastoma","volume":"16","author":"Nourizadeh","year":"2025","journal-title":"Discov. Oncol."},{"issue":"399","key":"10.1016\/j.drup.2026.101412_bib163","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib164","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21407-w","article-title":"Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages","volume":"12","author":"Ochocka","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101412_bib165","first-page":"3","article-title":"CXCL12 Mediates Trophic Interactions between Endothelial and Tumor Cells in Glioblastoma","volume":"7","author":"Okamoto","year":"2012","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.drup.2026.101412_bib166","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179853","article-title":"Spatial analysis of recurrent glioblastoma reveals perivascular niche organization","volume":"9","author":"Onubogu","year":"2024","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041342","article-title":"DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets","volume":"15","author":"Ozair","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.drup.2026.101412_bib168","first-page":"1967","article-title":"An overview of MCT1 and MCT4 in GBM: small molecule transporters with large implications","volume":"8","author":"Park","year":"2018","journal-title":"Am. J. Cancer Res"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib169","article-title":"CAR-T cell therapy for the treatment of adult high-grade gliomas","volume":"8","author":"Park","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"16","key":"10.1016\/j.drup.2026.101412_bib170","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1073\/pnas.1525349113","article-title":"Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages","volume":"113","author":"Peterson","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.drup.2026.101412_bib171","doi-asserted-by":"crossref","DOI":"10.3390\/cells8111398","article-title":"Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment","volume":"8","author":"Piperi","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib172","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02566-0","article-title":"T-cell repertoire diversity: friend or foe for protective antitumor response?","volume":"41","author":"Porciello","year":"2022","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.drup.2026.101412_bib173","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib174","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01701-6","article-title":"Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects","volume":"18","author":"Qin","year":"2025","journal-title":"J. Hematol. & Oncol."},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib175","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","article-title":"Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes","volume":"186","author":"Rahim","year":"2023","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib176","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2326-6066.CIR-23-0211","article-title":"Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH\u2013Wild-Type High-Grade Gliomas","volume":"12","author":"Ran","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib177","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/neuonc\/noab228","article-title":"Glioblastoma genetic drivers dictate the function of tumor-associated macrophages\/microglia and responses to CSF1R inhibition","volume":"24","author":"Rao","year":"2022","journal-title":"Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib178","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28523-1","article-title":"T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10","volume":"13","author":"Ravi","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib179","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","article-title":"Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma","volume":"40","author":"Ravi","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib180","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17040508","article-title":"Nanomedicine-Enhanced Radiotherapy for Glioblastoma: Advances in Targeted Therapy and Adaptive Treatment Strategies","volume":"17","author":"Rawoj\u0107","year":"2025","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib181","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s10637-020-00950-1","article-title":"A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma","volume":"38","author":"Reardon","year":"2020","journal-title":"Investig. N. Drugs"},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib182","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.drup.2026.101412_bib183","doi-asserted-by":"crossref","first-page":"v347","DOI":"10.1093\/neuonc\/noaf201.1374","article-title":"EXTH-40. Targeting the adenosine A2A receptor enhances the efficacy of low dose temozolomide in a murine glioma model","volume":"27","author":"Repiton","year":"2025","journal-title":"Neuro-Oncol."},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib184","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib185","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.drup.2026.101412_bib186","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.molmed.2025.01.014","article-title":"Spatial biology \u2013 unravelling complexity within the glioblastoma microenvironment","volume":"31","author":"Robinson","year":"2025","journal-title":"Trends Mol. Med."},{"issue":"8","key":"10.1016\/j.drup.2026.101412_bib187","doi-asserted-by":"crossref","DOI":"10.3390\/ph17080973","article-title":"A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma","volume":"17","author":"Rolfe","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib188","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2395067","article-title":"Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade","volume":"13","author":"Rwandamuriye","year":"2024","journal-title":"OncoImmunology"},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib189","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070950","article-title":"Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges","volume":"11","author":"Saenz-Anto\u00f1anzas","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib190","article-title":"Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases","volume":"20","author":"Sandhbor","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib191","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nm.4347","article-title":"Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+ T cells","volume":"23","author":"Sanyal","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib192","article-title":"Therapeutic approaches to modulate the immune microenvironment in gliomas","volume":"8","author":"Sarantopoulos","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.drup.2026.101412_bib193","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.617385","article-title":"Immunosuppression in Gliomas via PD-1\/PD-L1 Axis and Adenosine Pathway","volume":"10","author":"Scheffel","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib194","doi-asserted-by":"crossref","first-page":"39","DOI":"10.15252\/emmm.201505505","article-title":"Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma","volume":"8","author":"Scholz","year":"2015","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib195","article-title":"The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review","volume":"6","author":"Schonfeld","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib196","doi-asserted-by":"crossref","first-page":"97","DOI":"10.36401\/JIPO-23-34","article-title":"Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions","volume":"7","author":"Ser","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.drup.2026.101412_bib197","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00163","article-title":"Turning \u201cCold\u201d Into \u201cHot\u201d Tumors\u2014Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers","volume":"9","author":"Sevenich","year":"2019","journal-title":"Front. Oncol."},{"issue":"13","key":"10.1016\/j.drup.2026.101412_bib198","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib199","article-title":"Tumor microenvironment in glioblastoma: Current and emerging concepts","volume":"5","author":"Sharma","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib200","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s13311-022-01256-1","article-title":"Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice","volume":"19","author":"Shoaf","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib201","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.drup.2026.101412_bib202","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14121286","article-title":"The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma","volume":"14","author":"Sim\u00f5es","year":"2024","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib203","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.drup.2026.101412_bib204","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030314","article-title":"Differential Effects of Ang-2\/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma","volume":"11","author":"Solecki","year":"2019","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.drup.2026.101412_bib205","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1002\/1878-0261.13657","article-title":"Microglia and macrophages in glioblastoma: landscapes and treatment directions","volume":"18","author":"Solomou","year":"2024","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib206","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12060655","article-title":"Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status","volume":"12","author":"Squalli Houssaini","year":"2024","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.drup.2026.101412_bib207","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cac2.12285","article-title":"Intercellular communications and metabolic reprogramming as new predictive markers for immunotherapy responses in gastric cancer","volume":"42","author":"Sung","year":"2022","journal-title":"Cancer Commun."},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib208","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cells11050768","article-title":"New immunometabolic strategy based on cell type-specific metabolic reprogramming in the tumor immune microenvironment","volume":"11","author":"Sung","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101412_bib209","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf201.1852","article-title":"Single-cell profiling of peripheral and local immune compartments reveal unique genotype-independent prognostic immune signatures across isocitrate dehydrogenase-stratified glioma","author":"Sussman","year":"2025","journal-title":"Neuro-Oncol."},{"issue":"19","key":"10.1016\/j.drup.2026.101412_bib210","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2217\/nnm-2020-0132","article-title":"An Update of Nanoparticle-Based Approaches for Glioblastoma Multiforme Immunotherapy","volume":"15","author":"Taiarol","year":"2020","journal-title":"Nanomedicine"},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib211","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12576-016-0435-6","article-title":"Inhibition of monocarboxylate transporter 1 suppresses the proliferation of glioblastoma stem cells","volume":"66","author":"Takada","year":"2016","journal-title":"J. Physiol. Sci."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib212","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11614-x","article-title":"A STAT3-based gene signature stratifies glioma patients for targeted therapy","volume":"10","author":"Tan","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib213","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.drup.2026.101412_bib214","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/cns.13649","article-title":"Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment","volume":"27","author":"Tang","year":"2021","journal-title":"CNS Neurosci. & Ther."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib215","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-med-060619-023155","article-title":"Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches","volume":"72","author":"Thompson","year":"2021","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib216","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib217","article-title":"Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity","volume":"5","author":"Tooley","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"3","key":"10.1016\/j.drup.2026.101412_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.prmedi.2025.100052","article-title":"Advances and challenges in personalized diagnosis and therapies for the management of recurrent glioblastoma","volume":"2","author":"Trivedi","year":"2025","journal-title":"Precis. Medicat."},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib219","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/bm500502n","article-title":"Thermoreversible Poly(ethylene glycol)-g-Chitosan Hydrogel as a Therapeutic T Lymphocyte Depot for Localized Glioblastoma Immunotherapy","volume":"15","author":"Tsao","year":"2014","journal-title":"Biomacromolecules"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib220","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36321-6","article-title":"T cell-independent eradication of experimental glioma by intravenous TLR7\/8-agonist-loaded nanoparticles","volume":"14","author":"Turco","year":"2023","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.drup.2026.101412_bib221","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/abc3fc","article-title":"Computational modelling of modern cancer immunotherapy","volume":"65","author":"Valentinuzzi","year":"2020","journal-title":"Phys. Med. & Biol."},{"key":"10.1016\/j.drup.2026.101412_bib222","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1672312","article-title":"Pan-cancer convergence of tumour\u2013immune microenvironment motifs revealed by CyTOF and imaging mass cytometry","volume":"16","author":"Vall\u00e9e","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib223","article-title":"The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival","volume":"12","author":"Valpione","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib224","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.drup.2026.101412_bib225","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202318028","article-title":"Tumor endothelial cell autophagy is a key vascular-immune checkpoint in melanoma","volume":"15","author":"Verhoeven","year":"2023","journal-title":"EMBO Mol. Med."},{"issue":"11","key":"10.1016\/j.drup.2026.101412_bib226","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.drup.2026.101412_bib227","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/neuonc\/nov138","article-title":"The CD40\/CD40L axis in glioma progression and therapy","volume":"17","author":"Walker","year":"2015","journal-title":"Neuro-Oncol."},{"issue":"10","key":"10.1016\/j.drup.2026.101412_bib228","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012308","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions","volume":"13","author":"Walton","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101412_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: From immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib230","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-021-02259-5","article-title":"The evolution of alternative splicing in glioblastoma under therapy","volume":"22","author":"Wang","year":"2021","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib231","doi-asserted-by":"crossref","DOI":"10.1038\/s41368-022-00160-w","article-title":"A comprehensive profile of TCF1+ progenitor and TCF1\u2212 terminally exhausted PD-1+CD8+ T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy","volume":"14","author":"Wang","year":"2022","journal-title":"Int. J. Oral. Sci."},{"key":"10.1016\/j.drup.2026.101412_bib232","first-page":"232","article-title":"Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy","volume":"16","author":"Wang","year":"2022","journal-title":"Bioact. Mater."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib233","doi-asserted-by":"crossref","DOI":"10.1007\/s44194-024-00031-y","article-title":"Glioma-associated macrophages: unraveling their dual role in the microenvironment and therapeutic implications","volume":"3","author":"Wang","year":"2024","journal-title":"Curr. Med."},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib234","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","article-title":"Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"issue":"36","key":"10.1016\/j.drup.2026.101412_bib235","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202509890","article-title":"Emerging cGAS-STING Agonist-Based Nanotherapeutics: Mechanistic Insights and Applications in Cancer Combination Therapy","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci."},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib236","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trecan.2022.12.008","article-title":"T cell exhaustion in malignant gliomas","volume":"9","author":"Watowich","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib237","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47185-9","article-title":"Microenvironmental reorganization in brain tumors following radiotherapy and recurrence revealed by hyperplexed immunofluorescence imaging","volume":"15","author":"Watson","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.drup.2026.101412_bib238","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040978","article-title":"Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours","volume":"14","author":"White","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101412_bib239","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcdb.2024.12.006","article-title":"Spatial omics shed light on the tumour organisation of glioblastoma","volume":"167","author":"Whittle","year":"2025","journal-title":"Semin. Cell & Dev. Biol."},{"key":"10.1016\/j.drup.2026.101412_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuno.2024.100041","article-title":"Navigating the immunosuppressive brain tumor microenvironment using spatial biology","volume":"15","author":"Widodo","year":"2024","journal-title":"ImmunoInformatics"},{"issue":"5","key":"10.1016\/j.drup.2026.101412_bib241","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"issue":"16","key":"10.1016\/j.drup.2026.101412_bib242","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","article-title":"T-cell Dysfunction in Glioblastoma: Applying a New Framework","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib243","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01899-4","article-title":"Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib244","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib245","article-title":"IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment","volume":"23","author":"Wu","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib246","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.drup.2026.101412_bib247","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.18632\/aging.204067","article-title":"Glioblastoma: two immune subtypes under the surface of the cold tumor","volume":"14","author":"Xiong","year":"2022","journal-title":"Aging"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib248","article-title":"The two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential","volume":"15","author":"Xiong","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.drup.2026.101412_bib249","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104963","article-title":"Glioblastoma vaccines: past, present, and opportunities","volume":"100","author":"Xiong","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.drup.2026.101412_bib250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.actbio.2025.01.050","article-title":"Nanoparticle-based drug delivery systems to modulate tumor immune response for glioblastoma treatment","volume":"194","author":"Xiong","year":"2025","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib251","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01710-5","article-title":"Panoramic spatial enhanced resolution proteomics (PSERP) reveals tumor architecture and heterogeneity in gliomas","volume":"18","author":"Xu","year":"2025","journal-title":"J. Hematol. & Oncol."},{"issue":"7","key":"10.1016\/j.drup.2026.101412_bib252","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.7150\/thno.40298","article-title":"Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib253","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib254","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-025-00784-0","article-title":"The progress and prospects of targeting the adenosine pathway in cancer immunotherapy","volume":"13","author":"Yang","year":"2025","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib255","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-025-02427-7","article-title":"Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment","volume":"11","author":"Yao","year":"2025","journal-title":"Cell Death Discov."},{"issue":"19","key":"10.1016\/j.drup.2026.101412_bib256","doi-asserted-by":"crossref","DOI":"10.3390\/cells14191540","article-title":"Integrated Spatial and Single-Cell Transcriptomics Reveals Poor Prognostic Ligand\u2013Receptor Pairs in Glioblastoma","volume":"14","author":"Yoshimoto","year":"2025","journal-title":"Cells"},{"issue":"23","key":"10.1016\/j.drup.2026.101412_bib257","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236092","article-title":"Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas","volume":"13","author":"Yu","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101412_bib258","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.csbj.2024.04.014","article-title":"Co-expression of immune checkpoints in glioblastoma revealed by single-nucleus RNA sequencing and spatial transcriptomics","volume":"23","author":"Yuan","year":"2024","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib259","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-025-03572-y","article-title":"Recent advances of engineering cell membranes for nanomedicine delivery across the blood\u2013brain barrier","volume":"23","author":"Yuan","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib260","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-cancerbio-061421-040258","article-title":"Strategies for Heating Up Cold Tumors to Boost Immunotherapies","volume":"7","author":"Zabransky","year":"2023","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"2","key":"10.1016\/j.drup.2026.101412_bib261","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"23","key":"10.1016\/j.drup.2026.101412_bib262","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1158\/1078-0432.CCR-21-1392","article-title":"Tumor Cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma","volume":"27","author":"Zhai","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.drup.2026.101412_bib263","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.cmet.2021.06.001","article-title":"Adipocyte iron levels impinge on a fat-gut crosstalk to regulate intestinal lipid absorption and mediate protection from obesity","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib264","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-03165-x","article-title":"Optimization of metabolism to improve efficacy during CAR-T cell manufacturing","volume":"19","author":"Zhang","year":"2021","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib265","article-title":"STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101412_bib266","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.2147\/IJN.S470315","article-title":"A Big Prospect for Hydrogel Nano-System in Glioma","volume":"19","author":"Zhang","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"1-2","key":"10.1016\/j.drup.2026.101412_bib267","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2004.12.009","article-title":"The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif","volume":"161","author":"Zhang","year":"2005","journal-title":"J. Neuroimmunol."},{"issue":"7449","key":"10.1016\/j.drup.2026.101412_bib268","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nature12155","article-title":"Psl trails guide exploration and microcolony formation in Pseudomonas aeruginosa biofilms","volume":"497","author":"Zhao","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib269","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-022-01731-z","article-title":"Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis","volume":"20","author":"Zhao","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib270","article-title":"Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy","volume":"9","author":"Zhao","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101412_bib271","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39933-0","article-title":"Spatial cellular architecture predicts prognosis in glioblastoma","volume":"14","author":"Zheng","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.drup.2026.101412_bib272","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.tips.2025.07.006","article-title":"Therapeutic potential of targeting macrophages and microglia in glioblastoma","volume":"46","author":"Zhou","year":"2025","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:24:34Z","timestamp":1783099474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":272,"alternative-id":["S1368764626000634"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101412","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking immune isolation in glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101412"}}